Bagal, SK; Omoto, K; Blakemore, DC; Bungay, PJ; Bilsland, JG; Clarke, PJ; Corbett, MS; Cronin, CN; Cui, JJ; Dias, R; Flanagan, NJ; Greasley, SE; Grimley, R; Johnson, E; Fengas, D; Kitching, L; Kraus, ML; McAlpine, I; Nagata, A; Waldron, GJ; Warmus, JS in [Bagal, Sharan K.; Omoto, Kiyoyuki; Blakemore, David C.] Pfizer Global R&D UK, Worldwide Med Chem, Portway Bldg,Granta Pk, Cambridge CB21 6GS, England; [Bungay, Peter J.] Pfizer Global R&D UK, Pharmacokinet Dynam & Metab, Portway Bldg,Granta Pk, Cambridge CB21 6GS, England; [Bilsland, James G.; Dias, Rebecca; Flanagan, Neil J.; Grimley, Rachel; Kitching, Linda; Waldron, Gareth J.] Pfizer Global R&D UK, Portway Bldg,Granta Pk, Cambridge CB21 6GS, England; [Corbett, Matthew S.; Warmus, Joseph S.] Pfizer Global R&D, Groton Labs, Eastern Point Rd, Groton, CT 06340 USA; [Cronin, Ciaran N.; Cui, J. Jean; Greasley, Samantha E.; Johnson, Eric; Kraus, Michelle L.; McAlpine, Indrawan; Nagata, Asako] Pfizer Global R&D, La Jolla Labs, 10770 Sci Ctr Dr, San Diego, CA 92121 USA; [Clarke, Philip J.; Fengas, David] Peakdale Mol, Discovery Pk House,Ramsgate Rd, Sandwich CT13 9ND, Kent, England published Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors in 2019, Cited 61. Recommanded Product: 2,4-Dichlorobenzoic acid. The Name is 2,4-Dichlorobenzoic acid. Through research, I have a further understanding and discovery of 50-84-0.
Tropomyosin receptor kinases (TrkA, TrkB, TrkC) are activated by hormones of the neurotrophin family: nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4). Moreover, the NGF antibody tanezumab has provided clinical proof of concept for inhibition of the TrkA kinase pathway in pain leading to significant interest in the development of small molecule inhibitors of TrkA. However, achieving TrkA subtype selectivity over TrkB and TrkC via a Type I and Type II inhibitor binding mode has proven challenging and Type III or Type IV allosteric inhibitors may present a more promising selectivity design approach. Furthermore, TrkA inhibitors with minimal brain availability are required to deliver an appropriate safety profile. Herein, we describe the discovery of a highly potent, subtype selective, peripherally restricted, efficacious, and well-tolerated series of allosteric TrkA inhibitors that culminated in the delivery of candidate quality compound 23.
Recommanded Product: 2,4-Dichlorobenzoic acid. Welcome to talk about 50-84-0, If you have any questions, you can contact Bagal, SK; Omoto, K; Blakemore, DC; Bungay, PJ; Bilsland, JG; Clarke, PJ; Corbett, MS; Cronin, CN; Cui, JJ; Dias, R; Flanagan, NJ; Greasley, SE; Grimley, R; Johnson, E; Fengas, D; Kitching, L; Kraus, ML; McAlpine, I; Nagata, A; Waldron, GJ; Warmus, JS or send Email.
Reference:
Chloride – Wikipedia,
,Chlorides – an overview | ScienceDirect Topics